New Strong Sell Stocks for October 15thZacks Investment Research · Oct 15, 2026
New Strong Sell Stocks for October 13thZacks Investment Research · Oct 13, 2026
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202GlobeNewsWire · Sep 9, 2026
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline ProgressGlobeNewsWire · Aug 5, 2026Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.09 | -$0.15 | Miss |
| May 6, 2026 | -$0.12 | -$0.09 | Beat |
| Mar 19, 2026 | -$0.11 | -$0.14 | Miss |
| Nov 5, 2025 | -$0.09 | -$0.10 | Miss |
| Aug 6, 2025 | -$0.06 | -$0.09 | Miss |
| May 7, 2025 | -$0.05 | -$0.05 | Beat |